摘要
目的:系统评价安罗替尼治疗晚期非小细胞肺癌的临床疗效和相关不良反应。方法:以“安罗替尼、非小细胞肺癌、恶性肿瘤”等为关键词,计算机检索如下数据库:PubMed,CNKI,万方医学网,FMRS等数据库,纳入安罗替尼治疗晚期非小细胞肺癌的随机对照研究(RCT),并用RevMan5.3软件进行Meta分析。结果:本文纳入7个研究,包括466例晚期非小细胞肺癌患者,所有研究均采用随机对照方法。Meta分析结果显示,安罗替尼治疗晚期非小细胞肺癌的有效率明显高于安慰剂组[RR = 1.87, 95% CI (1.42, 2.45), P 0.05)。结论:安罗替尼作为三线治疗晚期非小细胞肺癌的靶向药物可以显著提高治疗的有效率且不增加药物不良反应。
Objective: To systematically evaluate the clinical efficacy and related adverse reactions of anlotinib in the treatment of advanced non-small cell lung cancer. Methods: Taking “anlotinib, non-small cell lung cancer, malignant tumor” as the key words, the following databases were searched by com-puter: PubMed, CNKI, Wanfang medical network, FMRS and other databases, which were included in the randomized controlled study (RCT) of anlotinib in the treatment of advanced non-small cell lung cancer, and meta-analysis was performed with RevMan5.3 software. Results: Seven studies were included, including 466 patients with advanced non-small cell lung cancer. All the studies were randomized controlled. The results of meta-analysis showed that the effective rate of anlotinib in the treatment of advanced non-small cell lung cancer was significantly higher than that of place-bo group [RR = 1.87, 95% CI (1.42, 2.45), P 0.05). Conclusion: As a target drug for the third-line treatment of advanced non-small cell lung cancer, anlotinib can significantly improve the effective rate without increasing adverse drug reactions.
出处
《临床医学进展》
2023年第1期26-33,共8页
Advances in Clinical Medicine
